Back to top
more

Akari Therapeutics (AKTX)

(Delayed Data from NSDQ)

$1.20 USD

1.20
3,157

+0.01 (0.84%)

Updated Apr 26, 2024 11:33 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study

by Zacks Equity Research

Apellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients.

Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug

by Zacks Equity Research

Approval of Apellis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in the United States lends a significant boost to the company's growth prospects.

Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease

by Zacks Equity Research

The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.

Ekta Bagri headshot

Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More

by Ekta Bagri

Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.

Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease

by Zacks Equity Research

The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.

Alexion's Ultomiris Receives EU Approval for PNH in Adults

by Zacks Equity Research

Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.

Alexion Receives FDA Approval for Label Expansion of Soliris

by Zacks Equity Research

Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.

Alexion's sBLA for Ultomiris Gets Priority Review From FDA

by Zacks Equity Research

The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.

Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study

by Zacks Equity Research

Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.

Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up

by Zacks Equity Research

Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.

Alexion's Ultomiris Meets Primary Endpoint in aHUS Study

by Zacks Equity Research

Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.

Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3%

by Zacks Equity Research

Kadmon Holdings, Inc. (KDMN) was a big mover last session, as the company saw its shares more than 9% on the day amid huge volumes.

    Alder BioPharmaceuticals (ALDR) Jumps: Stock Rises 15.5%

    by Zacks Equity Research

    Alder BioPharmaceuticals, Inc. (ALDR) was a big mover last session, as the company saw its shares more than 15% on the day amid huge volumes.

      CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1%

      by Zacks Equity Research

      CRISPR Therapeutics AG (CRSP) was a big mover last session, as the company saw its shares more than 12% on the day amid huge volumes.

        Penumbra (PEN) Forms JV on Virtual Reality in Health Space

        by Zacks Equity Research

        Penumbra's (PEN) joint venture with Sixense Enterprises indicates formation of a leading digital health platform in the field of virtual reality technology.

          Audentes Therapeutics (BOLD) Jumps: Stock Rises 14.9%

          by Zacks Equity Research

          Audentes Therapeutics, Inc. (BOLD) was a big mover last session, as the company saw its shares nearly 15% on the day amid huge volumes.

            New Products Aid Boston Scientific, LOTUS Relaunch Lag Ails

            by Zacks Equity Research

            Boston Scientific (BSX) grows on product launches and international expansion. LOTUS relaunch delay hurts sales.

              Thermo Fisher Buys Phenom-World, Aids Analytical Instruments

              by Zacks Equity Research

              On completion of Phenom-World purchase, Thermo Fisher (TMO) plans to integrate the business into its Analytical Instruments segment.

                Anika Therapeutics Receives FDA Nod for Bone Repair Therapy

                by Zacks Equity Research

                Anika Therapeutics' (ANIK) FDA approved HA-based injectable bone repair therapy provides a commercial edge to regenerative portfolio.

                  PetMed Rides on Solid Reorders & New Orders Amid Competition

                  by Zacks Equity Research

                  PetMed (PETS) strives to implement several strategies to revitalize the top line, focusing on advertising efficiency to boost new order sales and shifting sales to higher margin items.

                    NutriSystem (NTRI) Adopts Multi-Brand Strategy for 2018

                    by Zacks Equity Research

                    NutriSystem's (NTRI) Turbo Plans and South Beach Diet likely to witness an increase in customers.

                      Array BioPharma (ARRY) Looks Good: Stock Adds 9.6% in Session

                      by Zacks Equity Research

                      Array BioPharma (ARRY) shares rose nearly 10% in the last trading session, amid huge volumes.

                        Amarin Corporation (AMRN) in Focus: Stock Moves 8.9% Higher

                        by Zacks Equity Research

                        Amarin Corporation plc (AMRN) was a big mover last session, as the company saw its shares rise nearly 9% on the day.

                          What Falling Estimates & Price Mean for Vascular Biogenics (VBLT)

                          by Zacks Equity Research

                          Vascular Biogenics (VBLT) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

                            Syros Pharmaceuticals (SYRS) in Focus: Stock Moves 12.7% Higher

                            by Zacks Equity Research

                            Syros Pharmaceuticals (SYRS) was a big mover last session, as the company saw its shares nearly 13% on the day amid huge volumes.